Re: Precedence in Gene Therapy Pricing
posted on
Jan 04, 2018 02:02AM
golfyeti - I would love to use your $10,000 price however the payer groups would not support it. From company presentations in the past they have already gone from $2,000 per year to $4,000 and now $5,000. My understanding is that this number was from doing market research with the payer groups to see where they would start balking at the price of drug versus the number needed to treat(NNT) and the potential overall cost for the patients that these groups insured. In a nut shell, how much they were willing to spend to save one event. Again from my understanding it was somewhere around $100,000 to save one event or $5,000 per patient per year. The payer groups are the single biggest factor in pricing the drug as they are the ones that would be paying for the bulk of sales. It's just fun with numbers time.
DYODD
tada